Skip to main content
Quest Diagnostics

Male Breast Cancer With Dual BRCA2 and BRIP1 Deleterious Gene Mutations

Male Breast Cancer With Dual BRCA2 and BRIP1 Deleterious Gene Mutations

Authors: Badve SB, Kim E, Sibia US, Borrego OT, Vara S, Damron A, Riker AI

Citation: Ochsner J. 2024 Summer;24(2):157-161. doi: 10.31486/toj.23.0119

Specialties: Genetics, Oncology

Disclaimer: One or more of the authors of this publication were employed at the time by AmeriPath, a subsidiary of Quest Diagnostics.

Related content

Conference Presentation
BRCA1 and BRCA2 Testing When a Familial Variant is Reported
Conference Presentation
Detection of Germline and Somatic BRCA Mutations Using a 50 Gene Next Generation Sequencing Panel
Audio Podcast
Optimize Oncology Care with Clinical Pathways
Audio Podcast
Exploring Digital Pathology and Artificial Intelligence
On-Demand Webinar
Hereditary Cancer Care Starts in Primary Care
Test FAQ
Hereditary Breast Cancer Panel
Test FAQ
BRCA Panel Plus

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.